In 2018, in preparation of FDA submission, Hemanext completed a clinical study for the Hemanext ONE® RBC Processing and Storage System.
2018
Recent Posts
- Hemanext Announces Close of Series B-2 Equity Funding Round
- Hemanext Inc. Announces First Patients Treated In A Clinical Trial Investigating the Efficacy of the Hemanext ONE® Red Blood Cell Processing and Storage System
- Hemanext signs agreement with Hemara Bio, a healthcare distributor in the U.A.E., to provide hospitals and clinicians across the GCC Region with Hemanext ONE® system
- Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.”
- Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study